Low-Density Lipoprotein Test Market Scope, Share Analysis And Growth 2025

Built for executives and teams involved in growth planning, this research offers a data-driven view of the low-density lipoprotein test industry’s direction and competitive environment.

What Is The Current Outlook For The Low-Density Lipoprotein Test Market By 2025?
The low-density lipoprotein test market size has grown steadily in recent years. It will grow from $8.52 billion in 2024 to $8.83 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to research advancements in cardiovascular medicine, increased awareness of heart health, shift in treatment paradigms, clinical guidelines and recommendations, focus on preventive healthcare.

The low-density lipoprotein test market size is expected to see strong growth in the next few years. It will grow to $10.91 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing healthcare expenditure, aging population demographics, rise in cardiovascular disease burden, shift towards personalized medicine, healthcare policy and guidelines. Major trends in the forecast period include rising cardiovascular disease prevalence, emphasis on preventive healthcare, personalized medicine and treatment, focus on health awareness and education, regulatory guidelines and recommendations.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9395&type=smp

What Are The Key Driving Factors For The Growth Of The Low-Density Lipoprotein Test Market?
The rise in the prevalence of cardiovascular diseases is expected to propel the growth of the low-density lipoprotein test market going forward. Cardiovascular diseases refer to a type of condition that affects the heart or blood vessels. The LDL test is used to treat cardiovascular diseases by directly measuring low-density lipoprotein levels in the heart. For instance, in February 2024, according to the UK Parliament, a UK-based governing body, heart, and circulatory diseases account for about 25% of all deaths in England, resulting in more than 140,000 fatalities annually and approximately 480 each day, or one death every three minutes. Therefore, the rise in the prevalence of cardiovascular diseases is driving the growth of the low-density lipoprotein test market.

Global Low-Density Lipoprotein Test Market Report Segmentation
The low-density lipoprotein testmarket covered in this report is segmented –

1) By Product Type: LDL-C; LDL-P; LDL-B; Other Products
2) By Component: Kits; Reagents; Devices; Other Components
3) By Disease Type: Diabetes; Stroke; Atherosclerosis; Obesity; Dyslipidaemia; Carotid Artery Disease; Peripheral Arterial Disease; Angina; Other Disease Types
4) By Distribution Channel: Direct Tenders; Retail
5) By End User: Hospitals; Clinics; Ambulatory Care; Research Laboratory; Other End Users

Subsegments:
1) By LDL-C (Low-Density Lipoprotein Cholesterol): Direct Measurement Tests; Calculated LDL-C Tests
2) By LDL-P (Low-Density Lipoprotein Particle Number): NMR (Nuclear Magnetic Resonance) Tests; Other Particle Counting Methods
3) By LDL-B (Low-Density Lipoprotein Particle Size): Gradient Gel Electrophoresis; Other Size Measurement Techniques
4) By Other Products; Lipid Panel Tests: Genetic Testing For Dyslipidemia; Point-Of-Care Testing Devices

Low-Density Lipoprotein Test Market Emerging Trends And Opportunities
Product innovations are a key trend gaining popularity in the low-density lipoprotein test markets. Major companies operating in the low-density lipoprotein test market are introducing innovative products to sustain their position in the market. For instance, in July 2023, Numares Health, a Germany-based health diagnostic company launched the AXINON LDL-p Test System. It is an FDA-cleared diagnostic tool that provides a more detailed assessment of lipoproteins, offering insights into cardiac function beyond standard LDL-C measurements. Utilizing nuclear magnetic resonance (NMR) spectroscopy, the system incorporates advanced diagnostic algorithms to enhance accuracy. It helps physicians better manage patients at elevated risk for cardiovascular disease, particularly those with cardiometabolic risk factors.

Who Are The Leading Players In The Low-Density Lipoprotein Test Market?
Major companies operating in the low-density lipoprotein test market include Abbott Laboratories, Qiagen N.V., Randox Laboratories Ltd., Eurofins Scientific SE, Danaher Corporation, Bio-Rad Laboratories Inc., OPKO Health Inc., DiaSorin S.p.A., Boster Biological Technology Ltd., Rockland Immunochemicals Inc., Sekisui Diagnostics LLC, DiaSys Diagnostic Systems GmbH, Eurolyser Diagnostica GmbH, Diazyme Laboratories Inc., Cell Biolabs Inc, Home Access Health Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Quest Diagnostics Incorporated, SpectraCell Laboratories Inc., Siemens Healthineers, Laboratory Corporation of America Holdings, Merck KGaA, F Hoffmann-La Roche Ltd., Agilent Technologies Inc., BioVision Incorporated, Abcam plc, BioAssay Systems, BioChain Institute Inc., BioLegend Inc., Enzo Life Sciences Inc., GenScript Biotech Corporation

View the full low-density lipoprotein test market report here:
https://www.thebusinessresearchcompany.com/report/low-density-lipoprotein-test-global-market-report

Which Region Is Projected To Hold The Largest Market Share In The Global Low-Density Lipoprotein Test Market By 2029?
North America was the largest region in the Low-Density Lipoprotein Test market in 2024. The regions covered in the low-density lipoprotein test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company